Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) announced its quarterly earnings results on Thursday. Here are the key takeaways from Corvus Pharmaceuticals’ conference call:Get Corvus Pharmaceuticals alerts:Cash runway extended into Q2 2028 following $189.4 million in net proceeds from a first-quarter follow-on offering; Corvus ended June with $215.2 million in cash, equivalents and marketable securities. Corvus Pharmaceuticals Price PerformanceCorvus Pharmaceuticals stock traded up $0.06 during midday trading on Friday, reaching $13.92. The Goldman Sachs Group began coverage on Corvus Pharmaceuticals in a research note on Friday, April 17th. See AlsoReceive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.